Journal ArticleOPEN ACCESS

A case of unresectable combined hepatocellular and cholangiocarcinoma treated with atezolizumab plus bevacizumab

  • Saito N
  • Hatanaka T
  • Nakano S
  • et al.
Clinical Case Reports (2022) 10(7)
DOI: 10.1002/ccr3.6129
N/ACitations
Citations of this article
7Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

An 81‐year‐old man initially underwent right hepatic lobectomy for liver cancer and was pathologically diagnosed with combined hepatocellular and cholangiocarcinoma (CHC). At 13 months after resection, multiple lymph node metastases were observed. We started atezolizumab plus bevacizumab (Atez/Bev), achieving a 7.5‐month progression‐free survival. Atez/Bev might exhibit efficacy for CHC patients.

Cite

CITATION STYLE

APA

Saito, N., Hatanaka, T., Nakano, S., Hazama, Y., Yoshida, S., Hachisu, Y., … Uraoka, T. (2022). A case of unresectable combined hepatocellular and cholangiocarcinoma treated with atezolizumab plus bevacizumab. Clinical Case Reports, 10(7). https://doi.org/10.1002/ccr3.6129

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free